Gene · 2192
NIH grants1,030
NIH grants whose papers are about the gene, through NIH's grant-paper links.
101 to 120 of 1,030
Download this page as JSON| Grant | Title | FBLN1 papers | Newest fiscal year |
|---|---|---|---|
| P50HD105351 | Boston Children's Hospital/HMS Intellectual and Developmental Disabilities Research Center | 1 | 2025 |
| P51OD011107 | California National Primate Research Center | 1 | 2025 |
| R01AG051658 | AD/ADRD and biological aging proteomic signatures in the etiopathology of delirium and its associated long-term cognitive decline | 1 | 2025 |
| R01AG067151 | Single-Cell Transcriptional and Epigenomic Dissection to Identify Therapeutic Targets for ALS and FTD | 1 | 2025 |
| R01AG079864 | Brain Vulnerability in Delirium and Alzheimer’s Disease and Related Dementias: Intersection of Polygenic Risk and Inflammation | 1 | 2025 |
| R01AI040098 | B lymphocyte Migration and Homeostasis | 1 | 2025 |
| R01AI049313 | T cell responses to CD1-restricted lipids in tuberculosis | 1 | 2025 |
| R01AI091627 | Notch Signaling in Alloimmunity | 1 | 2025 |
| R01AI153363 | Determinants of differentiation and maintenance of PD-1+ CD8 T cells | 1 | 2025 |
| R01AI176660 | Defining the role of IL-18 in atopic dermatitis | 1 | 2025 |
| R01AR063070 | Skin-targeted Cell Therapy for Recessive Dystrophic Epidermolysis Bullosa | 1 | 2025 |
| R01AR063709 | Expanded fibroblast subset drives pathology in rheumatoid arthritis | 1 | 2025 |
| R01AR063759 | Defining the influence of RA genetic susceptibility factors on T cell antigen specificity and functional state | 1 | 2025 |
| R01AR079485 | Novel non-viral reprogramming strategies to treat Discogenic back pain via engineered extracellular vesicles | 1 | 2025 |
| R01CA096512 | Cell model for KSHV infection and genetic manipulation | 1 | 2025 |
| R01CA124332 | Regulation of KSHV replication by N6-methyladenosine (m6A) | 1 | 2025 |
| R01CA205406 | Leveraging Novel Randomized Clinical Trials of Vitamin D Supplementation in Patients with Colorectal Cancer: Impact on Survival and Anti-Tumor Immunity | 1 | 2025 |
| R01CA240301 | Dynamic Interactions of the Ovarian-Fallopian Axis in High Grade Serous Ovarian Cancer | 1 | 2025 |
| R01CA241410 | Precision Prostate Cancer Screening with Genetically Adjusted Prostate-Specific Antigen Levels | 1 | 2025 |
| R01CA241752 | Targeting MUC5AC mucin in breast cancer brain metastasis | 1 | 2025 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2192/grants?page=6